Journal
NATURE MEDICINE
Volume 27, Issue 8, Pages 1379-+Publisher
NATURE PORTFOLIO
DOI: 10.1038/s41591-021-01413-7
Keywords
-
Funding
- European Research Council (ERC) under the European Union's Horizon 2020 research and innovation programme [852223]
- Israeli Science Foundation [3963/19]
- Edmond J. Safra Center for Bioinformatics at Tel Aviv University
- European Research Council (ERC) [852223] Funding Source: European Research Council (ERC)
Ask authors/readers for more resources
Breakthrough SARS-CoV-2 infections post-vaccination may be caused by B.1.1.7 or B.1.351 variants, indicating the importance of robust vaccination. Reduced vaccine effectiveness against these variants was observed in the study, highlighting the need for continued surveillance and enhanced vaccination efforts.
At early time points after vaccination with a single dose or two doses of the BNT162b2 mRNA COVID-19 vaccine, breakthrough SARS-CoV-2 infections can be disproportionately caused by the B.1.1.7 or B.1.351 variants of concern, underlining the need to ensure rapid and complete vaccination. The BNT162b2 mRNA vaccine is highly effective against SARS-CoV-2. However, apprehension exists that variants of concern (VOCs) may evade vaccine protection, due to evidence of reduced neutralization of the VOCs B.1.1.7 and B.1.351 by vaccine sera in laboratory assays. We performed a matched cohort study to examine the distribution of VOCs in infections of BNT162b2 mRNA vaccinees from Clalit Health Services (Israel) using viral genomic sequencing, and hypothesized that if vaccine effectiveness against a VOC is reduced, its proportion among breakthrough cases would be higher than in unvaccinated controls. Analyzing 813 viral genome sequences from nasopharyngeal swabs, we showed that vaccinees who tested positive at least 7 days after the second dose were disproportionally infected with B.1.351, compared with controls. Those who tested positive between 2 weeks after the first dose and 6 days after the second dose were disproportionally infected by B.1.1.7. These findings suggest reduced vaccine effectiveness against both VOCs within particular time windows. Our results emphasize the importance of rigorously tracking viral variants, and of increasing vaccination to prevent the spread of VOCs.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available